SAG
RYTM icon

SageView Advisory Group’s Rhythm Pharmaceuticals RYTM Stock Holding History

SageView Advisory Group’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$3.21K Buy
+30
New +$3.18K ﹤0.01% 2092

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SageView Advisory Group's RYTM Position: Q4 2025 in Review

SageView Advisory Group opened a new position in Rhythm Pharmaceuticals (RYTM) in Q4 2025: 30 shares worth $3.21K. The stake represents ﹤0.01% of the portfolio and ranks #2092 among its holdings.

279 funds tracked by Wall St. Rank hold RYTM as of Q4 2025.

  • SageView Advisory Group held 30 shares of Rhythm Pharmaceuticals worth $3.21K as of Q4 2025.
  • Rhythm Pharmaceuticals was a new SageView Advisory Group position in Q4 2025.
  • Rhythm Pharmaceuticals made up ﹤0.01% of SageView Advisory Group's portfolio in Q4 2025, its #2092 holding.
  • 279 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q4 2025.

Based on SageView Advisory Group's 13F filing for Q4 2025, filed 17 Feb 2026.